When biotin isn’t available, that enzyme can’t do its job and cancer cells lose a key escape route. In laboratory tests, removing biotin slowed tumor growth because the cells could not adapt their metabolism. The effect grew stronger in the presence of mutations in a gene already linked to cancer, which seems to make tumors more dependent on the biotin-enabled pathway.
This work points toward therapies that could limit a cancer’s metabolic options and make existing treatments more effective. The idea raises practical questions about how to target biotin usage in tumors without harming healthy tissues and whether patients’ diets or genetics might change their response. Follow the link to read how researchers are connecting metabolism, genes, and potential new strategies to broaden who benefits from cancer treatments.
Cancer cells are known for their “glutamine addiction,” but many can escape this weakness by switching to alternative fuels. Researchers found that vitamin B7 acts like a metabolic “license,” enabling this escape route through a key enzyme. Without biotin, cancer cells lose that flexibility and stop growing. Mutations in a cancer-linked gene can make this vulnerability even stronger, offering a promising new target for therapy.
